Results 51 to 60 of about 47,297 (213)

Grading and Study of Biological Markers in Ductal Carcinoma in situ and Concurrent Infiltrating Ductal Carcinoma of Breast [PDF]

Journal of Clinical and Diagnostic Research, 2018
Introduction: Breast cancer is the most common cancer in women. Breast cancer has surpassed cervical cancer and is now the leading cause of cancer death; however, cervical cancer still remains common in rural areas.
Lovely George, Muktha Ramesh Pai
doaj   +1 more source

Complications and Clinical Outcomes Following Modified Endoscopic Denker's With Pyriform Aperture Preservation: A Prospective Analysis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background The modified endoscopic Denker's (MED) approach provides access to all maxillary sinus (MS) walls for resection of various MS and retromaxillary pathologies, but the anteromedial maxilla has historically been resected. This study determined complication rates and outcomes following MED with pyriform aperture (PA) preservation ...
Yasser Almansour, Lane Donaldson, Khaled Kashlan, Swapna Vemuri, Jun Jin, John R. Craig   +5 more
wiley   +1 more source

Development of immunocompetent models for primary and metastatic ER+ breast cancer

Animal Models and Experimental Medicine, EarlyView.
This study explores syngeneic, immunocompetent models of ER+ breast cancer in 129S6/SvEv mice, using trackable tumor cells to model both primary tumors and metastasis. The models show promise, while also revealing limitations for studying advanced disease and immune interactions.
Devon M. Bull, Jody Hazlett, Emily Schulpen, Sophie Tunnicliffe, Alexander D. McLellan, Anita K. Dunbier   +5 more
wiley   +1 more source

DUCTAL CARCINOMA IN SITU

European Journal of Breast Health, 2010
Atilla Soran
doaj   +2 more sources

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Carcinoma In Situ Involving Sclerosing Adenosis on Core Biopsy: Diagnostic Pearls to Aid the Practicing Clinician and Avoid Overtreatment

Oncology and Therapy, 2020
Introduction Involvement of pre-existing benign lesions by ductal carcinoma in situ (DCIS) or lobular neoplasia (LN) can present difficult diagnostic challenges, and can easily cause misdiagnosis of invasive carcinoma and over-management of localized ...
Dana Richards, Alberto A. Ayala, Yun Wu, Lavinia P. Middleton   +3 more
doaj   +1 more source

Challenges and Pitfalls to Diagnosing NUTM1‐Rearranged Neoplasia of the Pancreas by Cytology and Ancillary Studies

Diagnostic Cytopathology, EarlyView.
ABSTRACT Fine‐needle aspiration cytology specimens are frequently utilized for ancillary studies to identify diagnostic and prognostic information. This case highlights diagnostic pitfalls and challenges in diagnosing NUTM1‐rearranged neoplasia on pancreatic cytology.
Terrance J. Lynn
wiley   +1 more source

Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ

Clinics, 2013
OBJECTIVES: Biological markers that predict the development of invasive breast cancer are needed to improve personalized therapy for patients diagnosed with ductal carcinoma in situ.
Fernando N. Aguiar, Henrique N. Mendes, Cinthya S. Cirqueira, Carlos E. Bacchi, Filomena M. Carvalho   +4 more
doaj  

A new subtype of papillary ductal carcinoma in situ with tall cell and reversed polarity morphology: a rare case report

BMC Women's Health
Background According to previous studies, tall cell carcinoma with reversed polarity can be easily distinguished from ductal carcinoma in situ based on the absence of myoepithelium and a typical histologic feature.
Ruiqi Zhong, Ziyi Chang, Xiuhong Wang, Dingrong Zhong   +3 more
doaj   +1 more source